We are live on ! Find out more
JNP

Juniper Pharmaceuticals, Inc. Common Stock
JNP

Delisted

JNP was delisted on the 13th of August, 2018.

Back to rankings

0 hedge funds and large institutions have $0 invested in Juniper Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

45.63% less ownership

Funds ownership: 45.63% → 0% (-46%)

100% less funds holding

Funds holding: 48 → 0 (-48)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $44.1M → $0 (-$44.1M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 47

Holders
–
Holders Change
-48
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
47
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$6.54M
2
JAM
JW Asset Management
Florida
-$3.71M
3
BlackRock
BlackRock
New York
-$3.65M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.52M
5
BCM
Bridgeway Capital Management
Texas
-$3.19M

JNP Hedge Fund Activity: Q3 2018 in Review

0 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2018, worth a combined $0 — down 100% from $44.1M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of JNP and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $6.54M sold.

  • 0 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2018, down from 48 in Q2 2018.
  • Funds reported $0 of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 47 closed out, a net change of -47 holders.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Renaissance Technologies, an estimated $6.54M sold.

Based on aggregated 13F filings for Q3 2018.